The effect of the ATG16L1 Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma by Huijbers, A. et al.
LETTER TO THE EDITOR
Endocrine-Related Cancer (2012) 19 L15–L18The effect of the ATG16L1 Thr300Ala
polymorphism on susceptibility and
outcome of patients with epithelial
cell-derived thyroid carcinomaDear Editor
Epithelial cell-derived thyroid carcinoma (TC) is the
most common endocrine malignancy. Increasing
evidence suggests that autophagy, a complex process
of autodigestion in conditions of cellular stress, plays
an important role in the pathophysiology of the TC
malignant process. One of the main mammalian
autophagy proteins is autophagy related 16-like 1
(ATG16L1), which is essential for autophagosome
formation, induction of autophagy, and modulation of
inflammation (Saitoh et al. 2008). Subsequently,
defective autophagy in ATG16L1 knockout mice
results in an increased production of the proinflamma-
tory cytokine interleukin 1b (IL1b; Saitoh et al. 2008)
that is also known to affect the growth and
differentiation of different malignant cell types (Apte
& Voronov 2002).
Considering the potential role of both autophagy and
IL1b in the pathology of TC, we hypothesized that
genetic variation in ATG16L1 influences the suscep-
tibility for and the outcome of TC. One single
nucleotide polymorphism of the ATG16L1 gene
(c.898AOG, Thr300Ala, rs2241880) has been shown
to affect the autophagy process (Cooney et al. 2010)
and also to modulate production of IL1b in human cells
(Plantinga et al. 2011). We investigated whether this
ATG16L1 polymorphism is associated with the
susceptibility or clinical outcome of TC.
One hundred and thirty nine patients (75% women,
mean age 39G13 (S.D.) years) with histologically
confirmed TC (papillary (70%), follicular TC (24%), or
both (6%)), who visited the outpatient clinic at the
Department of Endocrinology of our centre, were
included. Primary treatment consisted of (near-) total
thyroidectomy in all patients and modified radical neck
dissections in patients with confirmed nodal metas-
tases, followed by ablation with radioactive iodine
(I131, RAI) of residual thyroid tissue. Initial cure isEndocrine-Related Cancer (2012) 19 L15–L18
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absence of anti-Tg antibodies, and no evidence of
locoregional or distant metastasis on the whole-body
iodine scans and/or neck ultrasonography at 6 months
after RAI ablation. Current remission was defined as
undetectable Tg in the absence of anti-Tg antibodies
and no evidence of loco-regional or distant metastases
at the last follow-up visit. Persistent disease was
defined as either detectable Tg or evidence of loco-
regional or distant metastases. The population-based
control group consisted of 1964 Dutch healthy controls
(48% women, mean age 61C10 (S.D.) years) from the
Nijmegen Biomedical Study, a population-based
survey conducted by the Department of Epidemiology
and Biostatistics and the Department of Clinical
Chemistry of the Radboud University Nijmegen
Medical Centre.
The results indicate that the ATG16L1 300Ala (G)
allele showed a clear trend towards a protective effect
on TC susceptibility in a gene dose-dependent model,
PZ0.054 (Table 1). The gene dose-dependent model
suggests a dominant model of action, with odds ratio
for Thr/Ala heterozygotes and Ala/Ala homozygotes of
0.67 and 0.57 respectively. Indeed, the dominant
model showed an odds ratio of 0.63 (PZ0.021),
whereas no significant association was observed in a
recessive model (PZ0.171). For these analyses,
gender was excluded as a possible confounder (data
not shown). The analysis of the association between the
ATG16L1 genotype and the clinical parameters
revealed no differences with respect to tumor size
(PZ0.432) and the current disease status (PZ0.308;
Table 2). In contrast, patients heterozygous or
homozygous for the 300Ala (G) allele had a higher
chance of successful ablation therapy (PZ0.017), were
treated with a lower cumulative RAI dose to achieve
remission (PZ0.014) and received a lower number
of treatments than patients with the Thr300Thr
genotype (PZ0.038). This observation has importantBritain
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Table 1 Difference in genotype frequencies between the patient and control group, and the effect of the genotypes on epithelial cell
derived thyroid carcinoma susceptibility
Patients Controls OR (95% CI) P valuea
Gene dose-dependent model Fisher’s exact test 0.054
Thr/Thr 38 (27%) 378 (19%) 1.00 (reference) 0.055b
Thr/Ala 69 (50%) 1029 (52%) 0.667 (0.441–1.008)
Ala/Ala 32 (23%) 557 (28%) 0.571 (0.351–0.931)
Total 139 1964
Dominant model
Thr/Thr 38 (27%) 378 (19%) 1.00 (reference) 0.021b
Thr/AlaCAla/Ala 101 (73%) 1586 (81%) 0.633 (0.429–0.935)
Total 139 1964
Recessive model
Thr/ThrCThr/Ala 107 (77%) 1407 (72%) 1.00 (reference) 0.171b
Ala/Ala 32 (23%) 557 (28%) 0.755 (0.503–1.135)
Total 139 1964
aP values are nominal without correction.
bCalculated by c2 analysis.
A Huijbers et al.: ATG16L1 genetic variants in thyroid carcinomaimplications considering the fact that, besides the
surgery, the treatment with RAI represents the only
effective treatment for patients with TC, including
those with metastatic disease. The disease becomesTable 2 Summary of genotype–phenotype association parameters
Variable Thr/Thr (%) Thr/Ala
T stage
T1 7 (18%) 20 (29
T2 14 (37%) 22 (32
T3 7 (18%) 12 (17
T4 4 (11%) 6 (9%
Tx 6 (16%) 9 (13
N stage
N0 18 (47%) 36 (52
N1 10 (26%) 22 (32
Nx 10 (26%) 11 (16
M stage
M0 22 (58%) 47 (68
M1 0 1 (2%
Mx 16 (42%) 21 (30
RAI treatments (n)b
0–1 19 (50%) 38 (55
R2 19 (50%) 31 (45
Cumulative RAI dose (GBq)
%3.7 4 (11%) 21 (30
3.8–7.4 15 (39%) 19 (28
O7.4 19 (50%) 29 (42
Disease status after ablation
Remission 17 (46%) 36 (52
Persistent 20 (54%) 33 (48
Missing data 1 0
Current disease status
Remission 28 (74%) 52 (75
Persistent 10 (26%) 14 (21
Recurrent 0 3 (4%
aCalculated by c2 analysis, P values are nominal without correction
bIncluding radio-ablation.
L16incurable when the tumor loses its ability to accumu-
late I131. These data imply that patients carrying a
300Ala (G) allele may have a better outcome than
subjects homozygous for the 300Thr (A) allele.within the Dutch patient group (nZ139)
(%) Ala/Ala (%) Total P valuea
0.432
%) 14 (44%) 41
%) 9 (28%) 45
%) 4 (13%) 23
) 1 (3%) 11
%) 4 (13%) 19
0.489
%) 18 (56%) 72
%) 14 (44%) 46
%) 0 (0%) 21
0.357
%) 27 (85%) 96
) 2 (6%) 3
%) 3 (9%) 40
0.038
%) 25 (78%) 82
%) 7 (22%) 57
0.014
%) 10 (31%) 35
%) 16 (50%) 50
%) 6 (19%) 54
0.017
%) 25 (78%) 78
%) 7 (22%) 60
0 1
0.308
%) 28 (88%) 108
%) 3 (9%) 27
) 1 (3%) 4
.
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Endocrine-Related Cancer (2012) 19 L15–L18In a previously published genome-wide association
study, no effect of the ATG16L1 Thr300Ala poly-
morphism on susceptibility to TC was observed in
patients from Iceland (Gudmundsson et al. 2009).
A plausible explanation may be represented by the
differences between the two populations studied.
While in The Netherlands, the incidence of TC is low
(Netea-Maier et al. 2008), this is far higher in Iceland
(Duntas & Doumas 2009). The volcanic nature of
Iceland has been invoked as a potential culprit, as the
incidence of TC in Iceland is much higher than that in
the founder populations from Denmark and Sweden
(Kilfoy et al. 2009). It is therefore rational to
hypothesize that the effect of these local geographical
factors that lead to the higher TC incidence in Iceland
would likely mask the moderate effect of the ATG16L1
polymorphism acting in low TC incidence countries
such as The Netherlands.
One possible explanation for the observed associ-
ation between the ATG16L1 genotype and TC is that
this effect is mediated through modulation of the
proinflammatory cytokine IL1b. Besides its functional
role in immune responses, IL1b also affects cell growth
and differentiation of different cell types. IL1b has
anti-proliferative effects on several malignant cell
lines, including some of the human epithelial cell-
derived TC cell lines (Kimura et al. 1992, Ohta et al.
1996). We therefore propose that genetic variants of
ATG16L1 that are shown to influence IL1b production
may affect TC risk through modulation of the IL1b
response. However, other effects of the ATG16L1
polymorphism on the ability of TC cells to prevent cell
death by induction of autophagy cannot be excluded.
In conclusion, we report that the 300Ala (G) allele of
ATG16L1 is associated with decreased risk for
epithelial cell-derived TC in a Dutch population.
Furthermore, we report that the 300Ala allele is
associated with a higher sensitivity to RAI, with less
chance of persistent disease after thyroidectomy and
RAI ablation. Although by itself the ATG16L1
genotype is not suitable as a sole prognostic marker,
this polymorphism may represent a new marker that
could be added to a complex multifactorial model to
predict the response of TC patients to RAI treatment.
Further investigations are needed to confirm our
observations. Furthermore, additional studies are
required to unravel the underlying mechanism.
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